Cipla Limited Total Liabilities
Cipla Limited total liabilities. Based on the latest financial reports, Cipla Limited (CIPLA) has total liabilities worth Rs71.39 Billion INR (≈ $772.10 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Cipla Limited to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cipla Limited (2004–2025)
Total liabilities of Cipla Limited from 2004 to 2025. This chart illustrates how Cipla Limited's total liabilities have evolved over time, based on quarterly financial data. Explore CIPLA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Cipla Limited Competitors by Total Liabilities
The table below lists competitors of Cipla Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BUREAU VERITAS ADR EO-12
F:4BV0
|
Germany | €5.29 Billion |
|
Mueller Industries Inc
NYSE:MLI
|
USA | $683.25 Million |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr29.16 Billion |
|
Renaissancere Holdings Ltd
NYSE:RNR
|
USA | $35.16 Billion |
|
JD HEALTH INTL LTD
F:8ZN
|
Germany | €22.72 Billion |
|
Nextpower Inc.
NASDAQ:NXT
|
USA | $1.71 Billion |
|
Lingyi iTech Guangdong Co
SHE:002600
|
China | CN¥31.34 Billion |
|
MAPFRE S.A.ADR 2 / EO-10
F:CMA
|
Germany | €50.49 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Cipla Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Cipla Limited's balance sheet.
Liquidity & Leverage Metrics
Cipla Limited Total Liabilities Ratios Explained
Cipla Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.13 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cipla Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cipla Limited (2004–2025)
The table below shows the annual total liabilities of Cipla Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs60.98 Billion ≈ $659.45 Million |
+3.09% |
| 2024-03-31 | Rs59.15 Billion ≈ $639.72 Million |
+2.88% |
| 2023-03-31 | Rs57.50 Billion ≈ $621.81 Million |
-3.91% |
| 2022-03-31 | Rs59.84 Billion ≈ $647.12 Million |
-8.87% |
| 2021-03-31 | Rs65.66 Billion ≈ $710.12 Million |
-13.66% |
| 2020-03-31 | Rs76.05 Billion ≈ $822.48 Million |
-11.76% |
| 2019-03-31 | Rs86.19 Billion ≈ $932.12 Million |
+4.11% |
| 2018-03-31 | Rs82.79 Billion ≈ $895.33 Million |
+2.78% |
| 2017-03-31 | Rs80.55 Billion ≈ $871.14 Million |
-13.03% |
| 2016-03-31 | Rs92.62 Billion ≈ $1.00 Billion |
+95.58% |
| 2015-03-31 | Rs47.36 Billion ≈ $512.13 Million |
0.00% |
| 2014-03-31 | Rs47.36 Billion ≈ $512.13 Million |
+79.37% |
| 2013-03-31 | Rs26.40 Billion ≈ $285.52 Million |
+54.27% |
| 2012-03-31 | Rs17.11 Billion ≈ $185.07 Million |
-12.87% |
| 2011-03-31 | Rs19.64 Billion ≈ $212.41 Million |
+40.44% |
| 2010-03-31 | Rs13.99 Billion ≈ $151.25 Million |
-44.26% |
| 2009-03-31 | Rs25.09 Billion ≈ $271.34 Million |
+26.88% |
| 2008-03-31 | Rs19.77 Billion ≈ $213.85 Million |
+67.94% |
| 2007-03-31 | Rs11.77 Billion ≈ $127.34 Million |
-20.18% |
| 2006-03-31 | Rs14.75 Billion ≈ $159.52 Million |
+39.34% |
| 2005-03-31 | Rs10.59 Billion ≈ $114.48 Million |
+10.72% |
| 2004-03-31 | Rs9.56 Billion ≈ $103.40 Million |
-- |
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more